Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes

Kern, C. and Müller, P. and Chaccour, C. and Liechti, M. E. and Hammann, F. and Duthaler, U.. (2023) Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes. Malar J, 22. p. 194.

[img] PDF - Published Version
Available under License CC BY (Attribution).


Official URL: https://edoc.unibas.ch/95258/

Downloads: Statistics Overview


BACKGROUND: Ivermectin (22,23-dihydroavermectin B(1a): H(2)B(1a)) is an endectocide used to treat worm infections and ectoparasites including lice and scabies mites. Furthermore, survival of malaria transmitting Anopheles mosquitoes is strongly decreased after feeding on humans recently treated with ivermectin. Currently, mass drug administration of ivermectin is under investigation as a potential novel malaria vector control tool to reduce Plasmodium transmission by mosquitoes. A "post-ivermectin effect" has also been reported, in which the survival of mosquitoes remains reduced even after ivermectin is no longer detectable in blood meals. In the present study, existing material from human clinical trials was analysed to understand the pharmacokinetics of ivermectin metabolites and feeding experiments were performed in Anopheles stephensi mosquitoes to assess whether ivermectin metabolites contribute to the mosquitocidal action of ivermectin and whether they may be responsible for the post-ivermectin effect. METHODS: Ivermectin was incubated in the presence of recombinant human cytochrome P(450) 3A4/5 (CYP 3A4/5) to produce ivermectin metabolites. In total, nine metabolites were purified by semi-preparative high-pressure liquid chromatography. The pharmacokinetics of the metabolites were assessed over three days in twelve healthy volunteers who received a single oral dose of 12 mg ivermectin. Blank whole blood was spiked with the isolated metabolites at levels matching the maximal blood concentration (C(max)) observed in pharmacokinetics study samples. These samples were fed to An. stephensi mosquitoes, and their survival and vitality was recorded daily over 3 days. RESULTS: Human CYP3A4 metabolised ivermectin more rapidly than CYP3A5. Ivermectin metabolites M1-M8 were predominantly formed by CYP3A4, whereas metabolite M9 (hydroxy-H(2)B(1a)) was mainly produced by CYP3A5. Both desmethyl-H(2)B(1a) (M1) and hydroxy-H(2)B(1a) (M2) killed all mosquitoes within three days post-feeding, while administration of desmethyl, hydroxy-H(2)B(1a) (M4) reduced survival to 35% over an observation period of 3 days. Ivermectin metabolites that underwent deglycosylation or hydroxylation at spiroketal moiety were not active against An. stephensi at C(max) levels. Interestingly, half-lives of M1 (54.2 +/- 4.7 h) and M4 (57.5 +/- 13.2 h) were considerably longer than that of the parent compound ivermectin (38.9 +/- 20.8 h). CONCLUSION: In conclusion, the ivermectin metabolites M1 and M2 contribute to the activity of ivermectin against An. stephensi mosquitoes and could be responsible for the "post-ivermectin effect".
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Epidemiology and Public Health (EPH) > Vector Biology > Vector Research and Control (Müller)
UniBasel Contributors:Müller, Pie
Item Type:Article, refereed
Article Subtype:Research Article
ISSN:1475-2875 (Electronic)1475-2875 (Linking)
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
edoc DOI:
Last Modified:06 Jul 2023 09:23
Deposited On:06 Jul 2023 09:23

Repository Staff Only: item control page